ABSTRACT
OBJECTIVE: The protective role of breastfeeding against severe acute lung disease in infants is well established, but its mechanism is unclear. Most hypotheses assume that breastfeeding confers similar passive protection to every infant; however, a few observations have suggested that the benefits of breast milk against severe lung disease may differ according to gender. The objective of this study was to determine whether the effect of breastfeeding on susceptibility to severe acute lung disease among infants at high risk is different for girls and boys. METHODS: A cohort was analyzed prospectively by use of 2 different strategies: (1) predictors of first episode of rehospitalization by univariate and multivariate analyses using robust Poisson regression and (2) mean number of rehospitalizations between groups using multiple regression negative binomial models. RESULTS: A total of 119 high-risk, very low birth weight infants were enrolled. Breast milk protected girls but not boys against severe acute lung disease. The interaction between breastfeeding and gender was clinically and statistically significant, even after adjustment for variables that can affect severity of acute lung disease. Disease was most severe in formula-fed girls (versus formula-fed boys). CONCLUSIONS: Breastfeeding decreased the risk for severe acute lung disease in girls but not in boys. These findings suggest that breast milk protection is not universally conferred by passive transfer of humoral immunity (which should be gender indifferent), show that respiratory symptoms may be amenable to nonspecific modulation, and identify nonbreastfed preterm infant girls as an at-risk group for severe acute lung disease.
Subject(s)
Breast Feeding , Infant, Premature, Diseases/prevention & control , Respiratory Tract Infections/prevention & control , Female , Humans , Infant , Infant, Newborn , Male , Prospective Studies , Sex FactorsABSTRACT
We conducted a prospective, observational study to characterize the clinical manifestations of respiratory infections caused by human metapneumovirus (hMPV) and other viruses in 194 premature infants and young children with chronic lung disease or congenital heart disease in Buenos Aires. Children had 567 episodes of respiratory illness and were monitored until they were 2 years old or until the completion of the study. hMPV elicited 12 infections (2%) year-round; 30% were of moderate or greater severity. Human parainfluenza virus type 3 caused 24 infections (4%), and 5 (25%) of 20 lung infections led to hospitalization. Respiratory syncytial virus (RSV) caused 33 episodes--17% of infections and 32% of hospitalizations during the respiratory season. None of the 10 children infected with influenza virus had severe disease. The present study of at-risk children suggests that hMPV and influenza virus are infrequent agents of severe disease and highlights the need for preventive interventions against RSV in developing countries.
Subject(s)
Heart Defects, Congenital/complications , Infant, Premature, Diseases , Lung Diseases/complications , Metapneumovirus/isolation & purification , Paramyxoviridae Infections/physiopathology , Respiratory Tract Infections/physiopathology , Adult , Argentina , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Infant, Premature , Infant, Premature, Diseases/physiopathology , Infant, Premature, Diseases/virology , Male , Orthomyxoviridae/isolation & purification , Parainfluenza Virus 3, Human/isolation & purification , Paramyxoviridae Infections/complications , Pneumonia, Viral/complications , Pneumonia, Viral/physiopathology , Pneumonia, Viral/virology , Prospective Studies , Respiratory Syncytial Virus, Human/isolation & purification , Respiratory Tract Infections/complications , Respiratory Tract Infections/virology , Severity of Illness IndexABSTRACT
The attachment protein (glycoprotein) of respiratory syncytial virus (RSV) has long been associated with disease potentiation and respiratory symptoms. The glycoprotein has a conserved cysteine-rich region (GCRR) whose function is unknown and which is not necessary for efficient viral replication. In this report, we show that the GCRR is a powerful inhibitor of the innate immune response against RSV, and that early secretion of glycoprotein is critical to modulate inflammation after RSV infection. Importantly, the GCRR is also a potent inhibitor of cytokine production mediated by several TLR agonists, indicating that this peptide sequence displays broad antiinflammatory properties. These findings have important implications for RSV pathogenesis and describe an inhibitor of TLR-mediated inflammatory responses that could have clinical applications.
Subject(s)
Cysteine , Immunity, Innate/drug effects , Respiratory Syncytial Viruses/physiology , Viral Envelope Proteins/pharmacology , Amino Acid Sequence , Animals , Antigens, CD/analysis , Conserved Sequence , Female , Glycophorins/analysis , Leukocytes, Mononuclear/immunology , Lipopolysaccharides/toxicity , Mice , Mice, Inbred C57BL , Molecular Sequence Data , NF-kappa B/metabolism , Peptide Fragments/chemistry , Peptide Fragments/pharmacology , Respiratory Syncytial Viruses/immunology , Viral Envelope Proteins/immunologyABSTRACT
In 1966, infants and children in the USA were immunized with a formalin-inactivated vaccine against respiratory syncytial virus. The vaccine was immunogenic but elicited mainly nonprotective antibody. Upon exposure to respiratory syncytial virus in the community, immunized children developed severe pulmonary disease characterized by bronchoconstriction and pneumonia. Two immunized infants died as toddlers after respiratory syncytial virus infection. Exploration of the mechanisms of disease has dominated the literature for decades. In this review, the pathogenesis of enhanced respiratory disease is discussed and the characteristics of protective and pathogenic respiratory syncytial virus vaccines are examined.